The patient then completed one cycle of anthracycline-based chemotherapy regimen: rituximab, etoposide, prednisone, vincristine, doxorubicin, and an additional 5 cycles of anthracycline-based chemotherapy regimen: rituximab, etoposide, prednisone, vincristine, doxorubicin with 25% vincristine (the dose was reduced for neuropathy) (Figure 2) – Targeting of Peptidase Inhibitor for their effects on the nervous system

The patient then completed one cycle of anthracycline-based chemotherapy regimen: rituximab, etoposide, prednisone, vincristine, doxorubicin, and an additional 5 cycles of anthracycline-based chemotherapy regimen: rituximab, etoposide, prednisone, vincristine, doxorubicin with 25% vincristine (the dose was reduced for neuropathy) (Figure 2). a monomorphic, CD20+, diffuse, large B-cell lymphoma, nongerminal center type. He was treated with reduced … Continue reading The patient then completed one cycle of anthracycline-based chemotherapy regimen: rituximab, etoposide, prednisone, vincristine, doxorubicin, and an additional 5 cycles of anthracycline-based chemotherapy regimen: rituximab, etoposide, prednisone, vincristine, doxorubicin with 25% vincristine (the dose was reduced for neuropathy) (Figure 2)